AKT1 and breast carcinoma: As a logical consequence, among the many causes that have been associated with resistance to anti-HER2 therapies in breast cancer, dysregulations in the signalling of the PI3K/AKT/mTOR pathway seem to play an important role [17,21], as we confirmed in our cellular models of acquired resistance (Figure 1 and Figure S1).